Abstract
  • Question 1: Does novel evidence support the use of PrEP in particular sub-populations, apart from persons bearing an occupational rabies exposure risk?
  • Question 2: Does novel evidence support the need for rabies booster doses in persons at continual or frequent risk of occupational rabies exposure?
  • Question 3: Can the duration of the entire course of current PREP regimens be reduced while maintaining immunogenicity and clinical protection?
  • Question 4: Can the number of doses administered in current PREP regimens be reduced while maintaining immunogenicity and clinical protection?
  • Question 5: Which (operational) parameters affect cost-effectiveness of intradermal (ID) compared to intramuscular (IM) administration route of PEP? a. in urban settings; b. in rural settings.
  • Question 6: Can the duration of the entire course of current PEP regimens be reduced while maintaining immunogenicity and clinical protection?
  • Question 7: Can the number of doses administered in current PEP regimens be reduced while maintaining immunogenicity and clinical protection?
  • Question 8: Does novel evidence support recommendations on modified PEP protocols versus current PEP protocols for specific risk groups of rabies exposed patients, such as: Immuno-compromised patients (e.g. HIV-infected); patients concurrently using antimalarial drugs; pregnant women; bat exposures (i.e. for bat lyssavirus)?
  • Question 9: Does a change in route of administration (IM or ID) during a single course of a PEP regimen affect immunogenicity of PEP?
  • Question 10: Are there novel approaches to RIG (-sparing) injection versus current practice as part of PEP for category III exposed patients?
  • Question 11: Is there clinical equivalence in the safe use of eRIG compared to hRIG in category III exposed patients?
  • Question 12: Is there clinical equivalence in the efficacious use of eRIG compared to hRIG in category III exposed patients?
  • Question 13: Can monoclonal antibodies (mAb) be safely and efficaciously administered in category III rabies-exposed patients compared to standard RIG?
  • Question 14: In cases of RIG shortage and constraints, can subcategories of patients be identified who should be given highest priority for RIG administration?

     
  • Evidence to recommendation table
  • Rabies